@charlottefraser21

Cell and Advanced Therapies Supply Chain Management Market Size, Share, Growth, Analysis and Forecast to 2030

2020-09-24T07:06:18.540Z

Roots Analysis has done a detailed study on Cell and Advanced Therapies Supply Chain Management Market: Focus on Technological Solutions (Cell Orchestration Platforms, Enterprise Manufacturing Systems, Inventory Management Systems, Laboratory Information Management Systems, Logistics Management Systems, Patient Management Systems, Quality Management Systems, Tracking & Tracing Systems, and Other Software), 2019-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

To order this 510+ page report, which features 185+ figures and 400+ tables, please visit this link

Key Market Insights

Presently, over 160 innovative, software-enabled systems are being used to efficiently manage and streamline various aspects of the complex supply chain of cell and advanced therapies
Company involved in this domain are putting in significant efforts to develop advanced software solutions and also differentiate their offerings, from those of other industry players, in order to maintain a competitive edge
North America is the major hub of innovation in this field, serving as the base for companies of all sizes, which are primarily engaged in developing cloud-based solutions for diverse applications
The cell and advanced therapies market is characterized by an elaborate value chain, involving a multitude of processes and several stakeholders, each having a discrete set of priorities and requirements
Increase in partnership activity reflects the growing interest of stakeholders in this industry; over 50% of reported deals were established to deploy software solutions for enhancing visibility and supply chain performance
An analysis of recent activity on Twitter reveals the increasing interest and ongoing efforts of industry stakeholders in providing needle-to-needle traceability and supply chain orchestration solutions
Given their cost saving potential across different processes and operations, we expect the cell and advanced therapy supply chain solutions market to grow at an annualized rate of around 25% over the next decade
In the mid-long term, the projected opportunity is anticipated to be well distributed across various global regions, different end uses / applications and mode of deployment of various proprietary software solutions
For more information, please visit https://www.rootsanalysis.com/reports/view_document/cell-therapies-supply-chain/260.html
Table of Contents
PREFACE
Scope of the Report
Research Methodology
Chapter Outlines
EXECUTIVE SUMMARY
INTRODUCTION
Context and Background
An Introduction to Cell and Advanced Therapies
Classification of Advanced Therapy Medicinal Products
Current Market Landscape
Overview of Cell and Advanced Therapies Supply Chain
Donor Eligibility and Selection
Sample Collection
Manufacturing
Logistics
Patient Verification and Treatment
Challenges Associated with the Cell and Advanced Therapies Supply Chain
Process Standardization
Packaging and Shipping Qualification
Validation of Storage Containers
Process Qualification
Chain of Custody Documentation
Demand Forecastin
Software Solutions for Cell and Advanced Therapies Supply Chain Management
Enterprise Manufacturing System
Laboratory Information Management System
Inventory Management System
Quality Management System
Logistics Management System
Patient Management System
Electronic Clinical Outcome Assessments System
Supply Chain Orchestration Platfor
Growth Drivers and Roadblocks
Recent Developments and Upcoming Trends
Blockchain Technology
Internet of Things
Augmented Reality
Big Data Analytics
Artificial Intelligence
CURRENT MARKET LANDSCAPE
Chapter Overview
Cell and Advanced Therapies Supply Chain Management: Overall Market Landscape
Analysis by Type of Software Solution
Analysis by Key Specification and Benefits Offered
Analysis by Application
Analysis by Mode of Deployment
Analysis by Scale of Management
Analysis by Regulatory Certifications / Accreditations
Analysis by End User
Cell and Advanced Therapies Supply Chain Management: Developer Landscape
Analysis by Year of Establishment
Analysis by Location of Headquarters
Analysis by Company Size
Analysis by Support Services Offered
Leading Developers: Analysis by Number of Software Solutions
COMPANY COMPETITIVENESS ANALYSIS
Chapter Overview
Methodology
Assumptions and Key Input Parameters
Competitiveness Analysis: Software Solution Providers
COP Developers
EMS Developers
IMS Developers
LIMS Developers
LMS Developers
PMS Developers
QMS Developers
TTS Developers
CELL AND ADVANCED THERAPIES SUPPLY CHAIN MANAGEMENT: COMPANY PROFILES
Chapter Overview
Brooks Life Sciences
Company Overview
Supply Chain Management Software Solution Portfolio
Recent Developments and Future Outlook
Cryoport
Company Overview
Financial Information
Supply Chain Management Software Solution Portfolio
Recent Developments and Future Outlook
MasterControl
Company Overview
Supply Chain Management Software Solution Portfolio
Recent Developments and Future Outlook
SAP
Company Overview
Supply Chain Management Software Solution Portfolio
Recent Developments and Future Outlook
Savsu Technologies
Company Overview
Financial Information
Supply Chain Management Software Solution Portfolio
Recent Development and Future Outlook
TraceLink
Company Overview
Financial Information
Supply Chain Management Software Solution Portfolio
Recent Developments and Future Outlook
SUPPLY CHAIN ORCHESTRATION PLATFORM: EMERGING TRENDS AND KEY PLAYERS
Chapter Overview
Supply Chain Orchestration Platforms
Key Functions of Supply Chain Orchestration Platforms
Advantages of Supply Chain Orchestration Platforms
Supply Chain Orchestration Platform Implementation Strategies
Building the Required Foundation
Incorporating an Appropriate Scheduling System
Integration with Core Systems / Processe
Supply Chain Orchestration Platform: Social Media Trends
Scope and Methodology
Historical Trends in Volume of Tweets
Popular Keyword
Key Industry Players
Be The Match BioTherapies®
Company Overview
Financial Information
MatchSource®: Software Description
Recent Developments and Future Outloo
Clarkston Consulting
Company Overview
Cell Therapy Orchestration Platform: Software Description
Recent Developments and Future Outloo
Haemonetics
Company Overview
Financial Information
EdgeCell®: Software Description
Recent Developments and Future Outlook
Hypertrust Patient Data Care
Company Overview
Hypertrust X-Chain: Software Description
Recent Developments and Future Outloo
Lykan Bioscience
Company Overview
Unnamed Software: Software Description
Recent Developments and Future Outlook
MAK-SYSTEM
Company Overview
T.C.S.: Software Description
Recent Developments and Future Outlook
sedApta
Company Overview
O.S.A.: Software Description
Recent Developments and Future Outlook
Stafa Cellular Therapy
Company Overview
Stafa Cellular Therapy Lab: Software Description
Recent Developments and Future Outlook
Title 21 Health Solutions
Company Overview
Cell Therapy Software: Software Description
Recent Developments and Future Outlook
TrakCel
Company Overview
Financial Information
Cell Orchestration Platform: Software Description
Recent Developments and Future Outlook
Vineti
Company Overview
Financial Information
Personalized Therapy Management Platform: Software Description
Recent Developments and Future Outlook
FUNDING AND INVESTMENT ANALYSIS
Chapter Overview
Types of Funding
Cell and Advanced Therapies Supply Chain Management: Funding and Investment Analysis
Analysis by Number of Funding Instances
Analysis by Amount Invested
Analysis by Type of Funding
Analysis by Number of Funding Instances and Amount Invested across Different Software Solutions
Most Active Players: Analysis by Number of Funding Instances
Most Active Investors: Analysis by Number of Funding Instances
Geographical Analysis by Amount Invested
Concluding Remarks
PARTNERSHIPS AND COLLABORATIONS
Chapter Overview
Partnership Models
Cell and Advanced Therapies Supply Chain Management: Recent Collaborations and Partnerships
Analysis by Year of Partnership
Analysis by Type of Partnership
Partner’s Focus Area
Analysis by Partner’s Focus Area
Analysis by Type of Platform and Partner’s Focus Area
Analysis by Type of Partnership Model and Partner’s Focus Area
Software Solution Analysis
Analysis by Type of Software Solutions
Analysis by Type of Platform and Partnership Model
Most Active Players: Analysis by Number of Partnerships
Geographical Analysis
Most Active Players
Intercontinental and Intracontinental Agreements
SUPPLY CHAIN UTILIZATION USE CASES
Chapter Overview
Cell and Advanced Therapies Supply Chain Management: Recent Platform Utilization Use Cases
Analysis by Year of Utilization
Analysis by Type of Partner
Most Active Users: Distribution by Number of Platform Utilization Instances
Geographical Distribution of Users

Analysis by Type of Software Solution
Most Active Players: Analysis by Number of Platform Utilization Agreements
Most Active Players: Regional Analysis by Number of Platform Utilization Agreements
Regional Distribution by Type of Software Solutions
Intercontinental and Intracontinental Agreements
STAKEHOLDER NEEDS ANALYSIS
Chapter Overview
Cell and Advanced Therapies Supply Chain Management: Needs of Different Stakeholders
Comparison of Stakeholder Needs
COST SAVINGS ANALYSIS
Chapter Overview
Key Assumptions and Methodology
Overall Cost Saving Potential of Supply Chain Management Software Solutions, 2019-2030
Cost Saving Potential in Sample Collection and Processing, 2019-2030
Cost Saving Potential in Manufacturing, 2019-2030
Cost Saving Potential in Logistics, 2019-2030
Cost Saving Potential in Patient Verification and Treatment Follow-up, 2019-2030
MARKET FORECAST
Chapter Overview
Key Assumptions and Forecast Methodology
Overall Cell and Advanced Therapies Supply Chain Management Solutions Market, 2019-2030
Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Application
Cell and Advanced Therapies Supply Chain Management Solutions Market for Sample Collection and Processing, 2019-2030
Cell and Advanced Therapies Supply Chain Management Solutions Market for, Manufacturing, 2019-2030
Cell and Advanced Therapies Supply Chain Management Solutions Market for, Logistics, 2019-2030
Cell and Advanced Therapies Supply Chain Management Solutions Market for Patient Verification and Treatment Follow-up, 2019-2030
Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by End User
Cell and Advanced Therapies Supply Chain Management Solutions Market for Biobanks, 2019-2030
Cell and Advanced Therapies Supply Chain Management Solutions Market for Cell Therapy Labs / Commercial Organizations, 2019-2030
Cell and Advanced Therapies Supply Chain Management Solutions Market for Hospitals / Medical Centers, 2019-2030
Cell and Advanced Therapies Supply Chain Management Solutions Market for Research Institutes, 2019-2030
Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Type of Software Solution
Cell Orchestration Platforms Market for Cell and Advanced Therapies Supply Chain Management, 2019-2030
Enterprise Manufacturing Systems Market for Cell and Advanced Therapies Supply Chain Management, 2019-2030
Inventory Management Systems Market for Cell and Advanced Therapies Supply Chain Management, 2019-2030
Laboratory Information Management Systems Market for Cell and Advanced Therapies Supply Chain Management, 2019-2030
Logistics Management Systems Market for Cell and Advanced Therapies Supply Chain Management, 2019-2030
Patient Management Systems Market for Cell and Advanced Therapies Supply Chain Management, 2019-2030
Quality Management Systems Market for Cell and Advanced Therapies Supply Chain Management, 2019-2030
Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Mode of Deployment
Cell and Advanced Therapies Supply Chain Management Market for Cloud-based Solutions, 2019-2030
Cell and Advanced Therapies Supply Chain Management Market for On-premises Solutions, 2019-2030
Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Scale of Operation
Cell and Advanced Therapies Supply Chain Management Market for Clinical Therapies, 2019-2030
Cell and Advanced Therapies Supply Chain Management Market for Commercial Therapies, 2019-2030
Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Geography
Cell and Advanced Therapies Supply Chain Management Solutions Market in North America, 2019-2030
Cell and Advanced Therapies Supply Chain Management Solutions Market in Europe, 2019-2030
Cell and Advanced Therapies Supply Chain Management Solutions Market in Asia-Pacific, 2019-2030
Cell and Advanced Therapies Supply Chain Management Solutions Market in Rest of the World, 2019-2030
Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Application, Type of Software Solution and Mode of Deployment
Cell and Advanced Therapies Supply Chain Management Solutions Market for Sample Collection and Processing, 2019-2030
Cell Orchestration Platforms Market for Sample Collection and Processing, 2019-2030
Cell Orchestration Platforms Market for Sample Collection and Processing: Cloud-based Solutions, 2019-2030
Cell Orchestration Platforms Market for Sample Collection and Processing: On-premises Solutions, 2019-2030
Enterprise Manufacturing Systems Market for Sample Collection and Processing, 2019-2030
Enterprise Manufacturing Systems Market for Sample Collection and Processing: Cloud-based Solutions, 2019-2030
Enterprise Manufacturing Systems Market for Sample Collection and Processing: On-premises Solutions, 2019-2030

Inventory Management Systems Market for Sample Collection and Processing, 2019-2030
Inventory Management Systems Market for Sample Collection and Processing: Cloud-based Solutions, 2019-2030
Inventory Management Systems Market for Sample Collection and Processing: On-premises Solutions, 2019-2030
Laboratory Information Management Systems Market for Sample Collection and Processing, 2019-2030
Laboratory Information Management Systems Market for Sample Collection and Processing: Cloud-based Solutions, 2019-2030
Laboratory Information Management Systems Market for Sample Collection and Processing: On-premises Solutions, 2019-2030
Logistics Management Systems Market for Sample Collection and Processing, 2019-2030
Logistics Management Systems Market for Sample Collection and Processing: Cloud-based Solutions, 2019-2030
Logistics Management Systems Market for Sample Collection and Processing: On-premises Solutions, 2019-2030
Patient Management Systems Market for Sample Collection and Processing, 2019-2030
Patient Management Systems Market for Sample Collection and Processing: Cloud-based Solutions, 2019-2030
Patient Management Systems Market for Sample Collection and Processing: On-premises Solutions, 2019-2030
Quality Management Systems Market for Sample Collection and Processing, 2019-2030
Quality Management Systems Market for Sample Collection and Processing: Cloud-based Solutions, 2019-2030
Quality Management Systems Market for Sample Collection and Processing: On-premises Solutions, 2019-2030
Cell and Advanced Therapies Supply Chain Management Solutions Market for Manufacturing, 2019-2030
Cell Orchestration Platforms Systems Market for Manufacturing, 2019-2030
Cell Orchestration Platforms Systems Market for Manufacturing: Cloud-based Solutions, 2019-2030
Cell Orchestration Platforms Systems Market for Manufacturing: On-premises Solutions, 2019-2030
Enterprise Manufacturing Systems Market for Manufacturing, 2019-2030
Enterprise Manufacturing Systems Market for Manufacturing: Cloud-based Solutions, 2019-2030
Enterprise Manufacturing Systems Market for Manufacturing: On-premises Solutions, 2019-2030
Inventory Management Systems Market for Manufacturing, 2019-2030
Inventory Management Systems Market for Manufacturing: Cloud-based Solutions, 2019-2030
Inventory Management Systems Market for Manufacturing: On-premises Solutions, 2019-2030

Laboratory Information Management Systems Market for Manufacturing, 2019-2030
Laboratory Information Management Systems Market for Manufacturing: Cloud-based Solutions, 2019-2030
Laboratory Information Management Systems Market for Manufacturing: On-premises Solutions, 2019-2030
Logistics Management Systems Market for Manufacturing, 2019-2030
Logistics Management Systems Market for Manufacturing: Cloud-based Solutions, 2019-2030
Logistics Management Systems Market for Manufacturing: On-premises Solutions, 2019-2030
Patient Management Systems Market for Manufacturing, 2019-2030
Patient Management Systems Market for Manufacturing: Cloud-based Solutions, 2019-2030
Patient Management Systems Market for Manufacturing: On-premises Solutions, 2019-2030
Quality Management Systems Market for Manufacturing, 2019-2030
Quality Management Systems Market for Manufacturing: Cloud-based Solutions, 2019-2030
Quality Management Systems Market for Manufacturing: On-premises Solutions, 2019-2030
Cell and Advanced Therapies Supply Chain Management Solutions Market for Logistics, 2019-2030
Cell Orchestration Platforms Market for Logistics, 2019-2030
Cell Orchestration Platforms Market for Logistics: Cloud-based Solutions, 2019-2030
Cell Orchestration Platforms Market for Logistics: On-premises Solutions, 2019-2030
Enterprise Manufacturing Systems Market for Logistics, 2019-2030
Enterprise Manufacturing Systems Market for Logistics: Cloud-based Solutions, 2019-2030
Enterprise Manufacturing Systems Market for Logistics: On-premises Solutions, 2019-2030
Inventory Management Systems Market for Logistics, 2019-2030
Inventory Management Systems Market for Logistics: Cloud-based Solutions, 2019-2030
Inventory Management Systems Market for Logistics: On-premises Solutions, 2019-2030
Laboratory Information Management Systems Market for Logistics, 2019-2030
Laboratory Information Management Systems Market for Logistics: Cloud-based Solutions, 2019-2030
Laboratory Information Management Systems Market for Logistics: On-premises Solutions, 2019-2030
Logistics Management Systems Market for Logistics, 2019-2030
Logistics Management Systems Market for Logistics: Cloud-based Solutions, 2019-2030
Logistics Management Systems Market for Logistics: On-premises Solutions, 2019-2030

Patient Management Systems Market for Logistics, 2019-2030
Patient Management Systems Market for Logistics: Cloud-based Solutions, 2019-2030
Patient Management Systems Market for Logistics: On-premises Solutions, 2019-2030
Cell and Advanced Therapies Supply Chain Management Solutions Market for Patient Verification and Treatment Follow-up, 2019-2030
Cell Orchestration Platforms Market for Patient Verification and Treatment Follow-up, 2019-2030
Cell Orchestration Platforms Market for Patient Verification and Treatment Follow-up: Cloud-based Solutions, 2019-2030
Cell Orchestration Platforms Market for Patient Verification and Treatment Follow-up: On-premises Solutions, 2019-2030
Inventory Management Systems Market for Patient Verification and Treatment Follow-up, 2019-2030
Inventory Management Systems Market for Patient Verification and Treatment Follow-up: Cloud-based Solutions, 2019-2030
Inventory Management Systems Market for Patient Verification and Treatment Follow-up: On-premises Solutions, 2019-2030
Patient Management Systems Market for Patient Verification and Treatment Follow-up, 2019-2030
Patient Management Systems Market for Patient Verification and Treatment Follow-up: Cloud-based Solutions, 2019-2030
Patient Management Systems Market for Patient Verification and Treatment Follow-up: On-premises Solutions, 2019-2030
EXECUTIVE INSIGHTS
Chapter Overview
Thermo Fisher Scientific
Company Snapshot
Interview Transcript: Bryan Poltilove, Former General Manager, Cell and Gene Therapy
Cell and Gene Therapy Catapult
Company Snapshot
Interview Transcript: Jacqueline Barry, Chief Clinical Officer
McKesson
Company Snapshot
Interview Transcript: Divya Iyer, Senior Director, Corporate Strategy and Business Development, and Jill Maddux, Director, Cell and Gene Therapy Product Strategy
TrakCel
Company Snapshot
Interview Transcript: Martin Lamb, Former Chief Business Officer
CONCLUDING REMARKS
Chapter Overview
Key Takeaways
APPENDIX 1: LIST OF ADDITIONAL SUPPLY CHAIN MANAGEMENT SOFTWARE SOLUTIONS
APPENDIX 2: TABULATED DATA
APPENDIX 3: LIST OF COMPANIES AND ORGANIZATIONS
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com
Contact Information
Roots Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
gaurav.chaudhary@rootsanalysis.com

Digital Therapeutics Market Report by 2030

2020-09-23T06:43:40.961Z

Recent advances in information technology and biomedical science have enabled the development of a number of versatile digital solutions that are capable of either mimicking or augmenting, the fundamental qualities of pharmacological interventions

Roots Analysis has announced the addition of “Digital Health Market: Focus on Digital Therapeutics (2nd Edition), 2020-2030 (Based on Type of Solution (Software Solution, Gaming Solution and Combination Solution), Type of Therapy (Curative and Preventive), and Purpose of Solution (Medication Replacement and Medication Augmentation” report to its list of offerings.

According to experts, digital therapeutic solutions are primarily based on behavior modification and are designed to address a variety of therapeutic needs across a wide range of disease indications. On the other hand, several digital solutions have been developed to enable remote doctor-patient consultations. Such solutions witnessed a surge in adoptions amidst the COVID-19 pandemic.

Key Market Insights

Nearly 230 digital therapeutic solutions are currently available / under development

Close to 45% of the aforementioned solutions are standalone software applications targeting more than 60 unique indications.

Over 85% of digital therapeutic solutions are intended to replace medication

Such solutions are currently available / being developed to treat neurological disorders (27%), mental health problems (24%), and certain metabolic disorders (24%). Alternatively, some digital health products are designed to augment the effect of conventional therapeutics and are currently being considered for treating substance use disorders and few mental health problems.

220+ clinical trials, focused on digital therapeutics, have been registered since 2004

Around 80,000 patients have been enrolled in clinical research initiatives aimed to validate the efficacy of digital therapeutics, and generate real world evidence concerning their efficacy and safety. Close to 50% of such trials have been / are being conducted in the US.

Nearly USD 1.9 billion invested by both private and public investors in this domain

~85% of the total capital raised for digital therapeutics-related initiatives was from venture capital investors, featuring over 370 participants.

Partnership activity in this field has grown at a CAGR of ~42%, between 2015 and 2019

More than 70% of the reported deals were established after 2017, with the maximum activity being reported in 2019. Majority of the instances captured in the report were focused on pilot product offering (29%) and research and development agreements (21%).

North America and Europe are anticipated to capture over 70% of the market share by 2030

The market in Asia-Pacific regions is anticipated to grow at a relatively faster pace (23.2%). In 2030, digital solutions targeting metabolic disorders are likely to represent the largest market share, in terms of revenues from product sales (26%), followed by those intended for mental health problems (20%) and neurological disorders (19%).

The USD 8.86 billion (by 2030) financial opportunity within the digital therapeutics market has been analyzed across the following segments:

Type of Solution

· Standalone Software Application

· Software Application + Device + Personal Coach

· Software Application + Device + AI Support

· Software Application + Device

· Software Application + AI Support

· Software Application + Personal Coach

· Other Types of Solutions

Purpose of Solution

· Medication Replacement

· Medication Augmentation

Type of Therapy

· Curative

· Preventive

Business Model

· Business to Consumer (Patients and Caregivers)

· Business to Business (Healthcare Providers, Payers, Employers and Pharmaceutical Companies)

Therapeutic Areas

· Cardiovascular Disorders

· Chronic Pain

· Mental Health Problems

· Metabolic Disorders

· Neurological Disorders

· Respiratory Disorders

· Sleep Disorders

· Substance Use Disorders

· Others

Key Geographical Regions

· North America

· Europe

· Asia-Pacific

· Rest of the world

The research covers brief profiles of key players engaged in the development of digital therapeutic solutions; other popular industry players featured in the report include:

· Akili Interactive

· Beats Medical

· Big Health

· Bold Health

· Click Therapeutics

· CureApp

· dreem

· Ehave

· Ginger

· Happify Health

· inMotion VR

· Kaia Health

· Lark Health

· Mahana Therapeutics

· MindMaze

· Noom

· NOVOSI

· Omada Health

· Palo Alto Health Sciences

· Pear Therapeutics

· Vida Health

· Welldoc

· ZOLL Medical

For more information, please click on the following link:

https://www.rootsanalysis.com/reports/view_document/digital-health-market-focus-on-digital-therapeutic-monitoring-and-diag/208.html

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

Gaurav.Chaudhary@rootsanalysis.com

Antibody Discovery Services and Platforms Market 2020-2030

2020-09-22T07:35:58.312Z

High target specificity and favorable safety profiles offered by antibody based pharmacological interventions has created a high demand for such molecules; the domain has witnessed an increased inflow of investments and collaboration opportunities.

Roots Analysis has announced the addition of “Antibody Discovery: Services and Platforms Market (3rd Edition), 2020-2030” report to its list of offerings.

The development of such biologics is inherently complex, and many drug developers are now seeking to optimize R&D efficiency and affiliated costs. As a result, innovator companies are outsourcing most of their discovery-stage operations to specialty contract research organizations (CROs), which offer a plethora of advanced technologies to cater to the evolving needs. It is also worth highlighting that stakeholders engaged in this domain are actively undertaking initiatives to develop interventions for SARS-CoV-2 virus.

Key Market Insights

Presently, more than 80 players claim to offer services for antibody discovery

Over 90% of the aforementioned players provide services for hit generation, followed by those offering services for antibody humanization (58%). It is worth mentioning that five service providers claim to have the required expertise to serve as one-stop-shops for all the antibody discovery steps.

More than 120 companies offer antibody discovery platforms

It is worth highlighting that close to 180 technologies focused on antibody discovery are presently available in the market. Further, nearly 50% platforms use library-based methods to discover antibodies. Amongst these, phage display is currently the most widely used technique. This is followed by single cell-based methods (20%).

Partnership activity within this domain has grown at a CAGR of 18%, between 2015 and 2020

In the last five years, more than 400 agreements were inked related to antibody discovery, with the maximum activity being reported in 2018. Majority of partnership deals signed within this domain were licensing agreements (25%), product development and commercialization agreements (24%), and R&D agreements (18%).

Nearly USD 7 billion has been invested in the antibody discovery domain, during 2016-2020

The aforementioned amount was raised across more than 140 funding instances. It is important to mention that, in 2019-2020, over USD 2 billion was raised by antibody discovery service and platform providers across close to 40 instances. Majority of the funding in this year was acquired through venture capital rounds (42%), grants (20%), and instances of initial public offering (10%).

The antibody discovery services market is anticipated to be worth over USD 6 billion by 2030

Majority of the market opportunity (60%) is expected to be generated from antibody services offered through phage display and hybridoma based methods, followed by those using transgenic animal based methods; this trend is unlikely to change in the foreseen future as well.

The licensing market opportunity for antibody discovery platforms is anticipated to grow at a CAGR of close to 10%, during 2020-2030

By 2030, North America is estimated to capture over 50% (in terms of revenues generated) share of the antibody discovery platforms market. It is worth mentioning that the market for antibody discovery platforms in Asia-pacific is anticipated to grow at a relatively faster pace, during the forecast period.

The USD 6.5 billion (by 2030) financial opportunity within the antibody discovery services market has been analyzed across the following segments:

Steps Involved in the Antibody Discovery Process

· Antigen Designing

· Hit Generation

· Lead Selection

· Lead Optimization

· Lead Characterization

Antibody Discovery Method Used

· Phage Display

· Hybridoma

· Transgenic Animal

· Yeast Display

· Single Cell

· Others

Nature of Antibody Generated

· Humanized

· Human

· Chimeric

· Murine

Key Geographical Regions

· North America

· Europe

· Asia Pacific and Rest of the World

The research includes detailed profiles of key players (listed below); each profile features an overview of the company, its financial information (if available), a description of the platform(s) / service(s) offered, details of recent developments related to antibody discovery and an informed future outlook.

· Abzena

· Abwiz Bio

· Aragen Bioscience

· BIOTEM

· ChemPartner

· Creative Biolabs

· Distributed Bio

· Harbour BioMed

· HD Biosciences

· ImmunoPrecise Antibodies

· Integral Molecular

· Kymab

· LakePharma

· Ligand Pharmaceuticals

· MorphoSys

· PX’Therapeutics

· Syd Labs

· Viva Biotech

· Wuxi Biologics

For more information, please click on the following link:

https://www.rootsanalysis.com/reports/view_document/antibody-discovery-services-and-platforms/213.html

About Roots Analysis

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

Gaurav.Chaudhary@rootsanalysis.com

Global RNAi Therapeutics Market Growth by 2030

2020-09-17T06:48:52.869Z

Roots Analysis has done a detailed study on RNAi Therapeutics Market (2nd Edition), 2019 - 2030: Focus on siRNA, miRNA, shRNA and DNA, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

Key Inclusions

· A detailed review of the overall landscape of companies developing RNAi therapeutics, including information on phase of development (marketed, clinical, and preclinical / discovery stage) of pipeline candidates, target disease indication(s), key therapeutic areas (oncological disorders, infectious diseases, genetic disorders, ophthalmic diseases, respiratory disorders, hepatic disorders, metabolic disorders, cardiovascular disorders, dermatological disorders, and others), type of RNAi molecule (siRNA, miRNA, shRNA, sshRNA and DNA), target genes, type of delivery system used, route of administration and special drug designations (if any).

· A competitiveness analysis of key players engaged in this domain, evaluating their respective product portfolios, type of RNAi molecule, target therapeutic areas, company size and year of establishment.

· An analysis of completed, ongoing and planned clinical studies for different types of RNAi molecules. The trials were analyzed on the basis of various relevant parameters, such as registration year, current status, phase of development, type of RNAi molecule, regional distribution of clinical trials and enrolled patient population.

· An in-depth analysis of the various patents that have been filed / granted related to RNAi therapeutics, since 2014. The analysis also highlights the key parameters associated with the patents, including information on patent type (granted patents, patent applications and others), publication year, regional applicability, CPC symbols, emerging focus areas, leading industry / non-industry players (in terms of the number of patents filed / granted), and patent valuation.

· An analysis of the various partnerships pertaining to RNAi therapeutics, which have been established till August 2019, based on various parameters, such as the type of partnership, year of partnership, target disease indications, therapeutic area, type of RNAi molecule, financial details (wherever applicable), focus area of collaboration and most active players.

· An analysis of the investments made at various stages of development in companies engaged in this domain, between 2014-2019, including seed financing, venture capital financing, IPOs, secondary offerings, debt financing, grants and other offerings.

· An analysis of the key promotional strategies that have been adopted by developers of marketed oligonucleotide therapeutics, namely Defitelio®, Exondys® and Onpattro®.

· A review of emerging technology platforms and delivery systems that are being used for targeted therapeutic delivery, featuring detailed profiles of technologies.

· Detailed profiles of drug candidates that are in the advanced stages of development (phase II/III and above), including information on their current development status, mechanism of action, route of administration, affiliated delivery technology, dosage, recent clinical trial results along with information on their respective developers.

· An elaborate discussion on the use of miRNA as a potential biomarker, along with a list of diagnostic kits that are either available in the market, or likely to be approved in the foreseen future.

The USD 9.2 billion (by 2030) financial opportunity within the RNAi therapeutics market has been analyzed across the following segments:

Key therapeutic areas

· Oncological disorders

· Infectious diseases

· Genetic disorders

· Ophthalmic disorders

· Hepatic disorders

· Respiratory disorders

Type of RNAi molecule

· siRNA

· miRNA

· shRNA

· sshRNA

· DNA

Route of administration

· Subcutaneous

· Intravenous

· Intradermal

· Intratumoral

· Intravitreal

· Oral

· Intramuscular

Key geographical regions

· North America

· Europe

· Asia Pacific and the Rest of the World

For more information, please click on the following link:

https://www.rootsanalysis.com/reports/view_document/rnai-therapeutics-market-2nd-edition-2019-2030/278.html

About Roots Analysis

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

Gaurav.Chaudhary@rootsanalysis.com

Global Prefilled Syringes Market Development, Overview, and Forecast to 2030

2020-09-15T06:24:49.877Z

Prefilled syringes present an attractive packaging option that doubles as an easy-to-use drug delivery device, and a product life cycle management tool. Consequently, they have become indispensable within the modern healthcare industry.

The financial opportunity within the prefilled syringes market has been analyzed across the following segments:

Key Inclusions

· An overview of the current market landscape of companies engaged in manufacturing prefilled syringes, providing information on year of establishment, company size, geographical location of the headquarters and manufacturing facilities, type of material used (glass and plastic), number of barrel chambers (single chamber and dual chamber), type of needle system (fixed needle system, luer lock and luer cone) and syringe volume.

· An overview of the current market landscape of companies that are developing drugs in combination with prefilled syringes, featuring information on year of establishment, company size, geographical location of the developers, target therapeutic area, phases of development, type of drug molecule, route of administration, approval year (for marketed products), dosage details (for marketed products) and other approved dosage forms (for marketed products).

· A detailed competitiveness analysis of the various prefilled syringes that we came across, taking into consideration the supplier power (based on the employee size of developer / manufacturer and their respective annual revenues) and key product specifications, such as number of chambers in the barrel, number of needle systems, volume of the barrel, technological advancement / user-friendliness and other distinguishing features.

· A list of marketed drugs / therapies and pipeline candidates that are likely to be developed in combination with prefilled syringes in the near future, shortlisted based on an in-depth analysis that takes into consideration various relevant parameters, such as route of administration, type of drug molecule, target indications, other available dosage forms (for approved drugs) and historical annual sales information (for approved drugs).

· An analysis presenting potential strategic partners (primarily drug developers) for prefilled syringe manufacturers (with regard to likely collaboration opportunities for combination product development) based on different parameters, such as pipeline strength, target therapeutic indication(s) and developer strength.

· An analysis of the various prefilled syringe combination product-related initiatives of big pharma players, based on parameters, such as current adoption (based on number of approved and under development prefilled syringe combination products) and likely future adoption (based on potential injectable product candidates in the pipeline that are likely to be delivered via prefilled syringes), target therapeutic area(s) and type of drug molecule.

· A review of the landscape of contract fill / finish services providers that offer services for prefilled syringes, featuring a list of active (large-sized) service providers and analysis based on a number of relevant parameters, such as year of establishment, company size, scale of operation (preclinical, clinical and commercial), type of drug molecule (biologics and small molecules), and geographical location of the service provider.

· A detailed discussion on various safety features (add-on and integrated devices) installed in recent versions of prefilled syringes and the companies involved in developing and manufacturing such solutions.

· An informative summary of various guidelines established and issued by major regulatory bodies for the approval of prefilled syringes, across different countries / geographical regions.

· Brief discussions of currently available specialty syringes, which include prefilled flush syringes, prefilled diluent syringe systems and prefilled contrast agent delivery systems.

· A case study on companies that are engaged in the manufacturing of autoinjectors, featuring brief profiles of key players in this domain; each profile includes an overview of the firm, and information on its respective product portfolio.

· Elaborate profiles of prominent prefilled syringe manufacturers engaged in this domain, featuring a brief overview of the company, its financial information (if available), information on product portfolio, recent developments and an informed future outlook.

The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:

Target therapeutic area

· Autoimmune disorders

· Infectious diseases

· Neurological disorders

· Blood disorders

· Oncological disorders

· Psychiatric disorders

· Respiratory disorders

· Cardiovascular disorders

· Metabolic disorders

· Ophthalmic diseases

· Orthopedic disorders

· Others

Type of syringe

· Specialty syringes

Type of syringe barrel material

· Glass

· Plastic

Number of barrel chambers

· Single chamber

· Dual chamber

Key geographical regions

· North America

· Europe

· Latin America

· Asia Pacific

· Middle East and Africa

For more information, please click on the following link:

https://www.rootsanalysis.com/reports/view_document/prefilled-syringes-market/284.html

About Roots Analysis

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

Gaurav.Chaudhary@rootsanalysis.com

Global Elastomeric Closure Components Market Headed for Growth and Expansion by 2030

2020-09-14T08:35:00.756Z

The materials used to fabricate pharmaceutical packaging components are extremely important to preserving the stability, efficacy and safety of drug formulations. In fact, according to the USFDA, in the last two years, there have been over 2,000 drug and device recalls owing to packaging-related concerns. Elastomeric closures, with various types of coatings (such as FluoroTec® and Teflon®), have emerged as a promising option for developing closures for pharmaceutical containers.

The USD 9.3 billion (by 2030) financial opportunity within elastomeric closures market has been analyzed across the following segments:

Key Inclusions

· A detailed assessment of the current market landscape of companies manufacturing elastomeric container closures, featuring information on the type of closure (cap, needle shield, plunger, seal, stopper, and tip cap), type of respective primary container(s) (vial, syringe, and cartridge), elastomeric material(s) used for fabricating the aforementioned closures (such as bromobutyl, chlorobutyl, and others), drug type(s) that are compatible with elastomeric closures, sterilization status of closures (pre-sterilized and unsterilized), affiliated sterilization technique (if the closure(s) is available in the pre-sterilized format), scale of production (small scale, and large scale), type of customization (if available), affiliated dimensions, along with compliance certifications of the product.

· A comprehensive analysis on the packaging trends of over 230 drug products (including both biologics and small molecule drugs) that were approved over the last five years (beginning 2014), featuring an assessment of the packaging requirements of various container-closure systems based on parameters, such as year of approval of drug, type of molecule, dosage form, route of administration, holding temperature, type of packaging material(s) used for manufacturing primary container and affiliated closure, and leading drug developers (in terms of number of drugs packaged using elastomeric closures).

· An analysis of various developments / recent trends related to elastomeric packaging materials, offering insights on [A] partnerships and collaborations established within the industry, and [B] recent global conferences related to pharmaceutical packaging industry.

· Elaborate profiles of key players in this domain (shortlisted on the basis of size of product portfolio), featuring a brief overview of the company (including information on company headquarters, year of establishment, number of employees, and key members of the executive team), financial information (if available), detailed description of proprietary elastomeric closures, recent developments, and an informed future outlook.

· A case study on the role of robotics in pharmaceutical manufacturing and fill / finish operations, highlighting the advantages of using automation / automated technologies in such processes. It includes profiles of industry players offering such equipment for the aseptic processing of pharmaceutical products.

· An elaborate discussion on emerging trends (such as focus on personalized therapies, shift towards more flexible packaging, upgrading packaging components to enhance drug product safety, and growing adoption of smart packaging solutions) that are likely to have an impact on the future adoption of elastomeric container-closure components in the pharmaceutical packaging industry. It also features a Harvey ball analysis, highlighting the relative effect of each trend on the overall pharmaceutical packaging industry.

· An in-depth analysis to estimate the current and future demand for elastomeric closures across key primary packaging containers, including vials, syringes and cartridges, in different regions for the period 2019-2030. Input parameters considered for this analysis include current supply of different primary packaging components and their respective closures and the estimated the proportion of elastomeric closures that are likely to be supplied, which is indicative of the demand.

The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:

Type of packaging container

· Vials

· Syringes

· Cartridges

Type of packaging closure

· Seal

· Stopper

· Cap

· Plunger

· Barrel

· Needle Shield

Sterilization status

· Pre-sterilized

· Unsterilized

Key geographical regions

· North America

· Europe

· Asia Pacific

· Rest of the World

For more information, please click on the following link:

https://www.rootsanalysis.com/reports/view_document/elastomeric-closures-market-focus-on-parenteral-containers-2019-2030/255.html

About Roots Analysis

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

Gaurav.Chaudhary@rootsanalysis.com

Market Growth of Global Biopharmaceutical Contract Manufacturing to Remain Sluggish through 2020 - 2030

2020-09-09T10:01:12.883Z

Owing to benefits, such as reduced manufacturing costs, availability of cheap and skilled labor, and a supportive regulatory landscape, biopharmaceutical developers from across the globe, are increasingly outsourcing their manufacturing operations to China based CMOs.

The USD 2.6 billion (by 2030) financial opportunity within the China biopharmaceutical contract manufacturing market has been analyzed across the following segments:

Key Inclusions

· A detailed review of the overall landscape of companies offering contract manufacturing services for biopharmaceuticals in China, along with information on year of establishment, company size, scale of operation (preclinical, clinical and commercial), location of headquarters, number of manufacturing facilities, as well as location of these facilities, type of business segment, type of manufacturing service(s) offered (process development and characterization, method validation and testing, analytical development, stability studies, quality assurance and control, scale-up, downstream processing, regulatory support, data analytics and reporting, and others), type of biologic(s) manufactured (peptides / proteins, antibodies, vaccines, cell therapies, gene therapies, antibody drug conjugates, vectors, biosimilars, nucleic acids and others), type of expression system(s) used (mammalian, microbial and others), type of bioreactor(s) used (single-use bioreactors and stainless steel bioreactors) and its mode of operation (batch, fed-batch and perfusion), type of packaging, and affiliations to regulatory accreditations and certifications (if any).

· An analysis of the various partnerships pertaining to biopharmaceutical manufacturing in China, which have been established since 2016, based on several parameters, such as the year of partnership, type of partnership model adopted, scale of operation, type of biologic, focus area of the deal, target indication, most active players (in terms of number of partnerships signed), and geography.

· An analysis of the various expansion initiatives undertaken by contract manufacturers in China, in order to augment their capabilities, over the period 2016-2020 (till February), taking into consideration several relevant parameters, such as year of expansion, type of expansion (capability expansion, capacity expansion, facility expansion and new facility), scale of operation of manufacturing facility, type of biologic and location of manufacturing facility.

· A clinical trial analysis of completed and active studies related to biopharmaceuticals that have been / are being / are likely to be conducted in China, based on trial registration year, trial phase, trial recruitment status, type of sponsor / collaborator, geography and number of patients enrolled.

· An estimate of the overall, installed capacity for manufacturing biopharmaceuticals, based on data reported by industry stakeholders in the public domain; it highlights the distribution of available biopharmaceutical production capacity on the basis of company size (small, mid-sized, large and very large firms), scale of operation (preclinical, clinical and commercial), key geographical regions (China, Hong-Kong, Taiwan) and expression system used.

· A review of recent initiatives undertaken by big pharma players in China for the manufacturing of biopharmaceuticals, highlighting trends across various parameters, such as number of initiatives, year of initiative, and benchmark analysis of big pharma players.

· A qualitative analysis, highlighting the various factors that need to be taken into consideration by drug / therapy developers while deciding whether to manufacture their respective products in-house or engage the services of a CMO.

· Elaborate profiles of key players that have a diverse range of capabilities for the development, manufacturing and packaging of biopharmaceutical products. Each profile features an overview of the company, its financial performance (if available), information on its service portfolio, details related to manufacturing capabilities and facilities, recent developments (partnerships and expansions), and an informed future outlook.

· A case study comparing the key characteristics of large molecule and small molecule drugs, along with details on the various steps involved in their respective manufacturing processes.

· A discussion on industry affiliated trends, key drivers and challenges, under a SWOT framework, which are likely to impact the evolution of this field. It also includes a Harvey ball analysis, highlighting the relative impact of each SWOT parameter on industry dynamics.

For more information, please click on the following link:

https://www.rootsanalysis.com/reports/view_document/china-biopharmaceutical-contract-manufacturing/313.html

About Roots Analysis

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

Gaurav.Chaudhary@rootsanalysis.com

RNAi Therapeutics Market is Expected to Reach 9.2 billion by 2030 | At CAGR 45%

2020-09-09T05:24:22.560Z

Key Market Insights

· Over 32,000 patents related to RNAi therapeutics, indicating the heightened pace of research, have been filed / granted in the last several years

· Presently, there is only one approved drug and over 150 product candidates, which are being evaluated for the treatment of a variety of disease indications, based on the RNAi principle

· In order to achieve a competitive edge, the drug developers are increasingly focusing on developing the robust pipeline molecules across different therapeutic areas

· Majority of the candidate therapies are currently in the early stages of development and are based on the siRNA approach; the innovation in this domain is being led by developers headquartered in the US

· Several trials evaluating various RNAi drug candidates against a wide range of therapeutic indications have been registered in the recent past

· Investors, having realized the opportunity within this emerging segment of the pharmaceutical industry, have invested over USD 5 billion in capital across 65 instances, in the period between 2014 and 2019

· The increasing interest in this field is reflected in recent partnership activity; majority of deals inked were R&D and licensing agreements, featuring the participation of both international and indigenous stakeholders

· In order to keep patients and healthcare professionals informed and aware of the developments in this field of medicine, companies are deploying diverse promotional strategies for their respective products

· Prevalent trends indicate that the market for RNAi therapeutics is poised to grow significantly as multiple late stage molecules are commercialized in the near future, for the treatment of different clinical conditions

TABLE OF CONTENTS

1. PREFACE

1.1. Scope of the Report

1.2. Research Methodology

1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

3.1. Chapter Overview

3.2. Historical Trends

3.2.1. Discovery of RNAi

3.2.2. RNAi Therapy Development Efforts

3.3. Mechanism of RNAi

3.3.1. Components of RNAi

3.3.2. Cellular Mechanism

3.4. Types of RNAi Molecules

3.4.1. siRNA

3.4.2. miRNA

3.4.3. shRNA

3.5. Applications of RNAi

3.6. Advantages and Disadvantages of RNAi

3.7. Regulatory Guidelines

3.8. Future Perspectives

4. COMPETITIVE LANDSCAPE

4.1. Chapter Overview

4.2. Marketed and Development Pipeline

4.2.1. Analysis by Type of RNAi Molecule

4.2.2. Analysis by Phase of Development

4.2.3. Analysis by Type of Target Gene

4.2.4. Analysis by Therapeutic Area

4.2.5. Analysis by Route of Administration

4.2.6. Analysis by Special Drug Designation

4.2.7. Key Players

4.3. Developer Landscape

4.3.1. Analysis by Year of Establishment

4.3.2. Analysis by Company Size

4.3.3. Analysis by Location of Headquarters

5. COMPANY COMPETITIVENESS ANALYSIS

5.1. Chapter Overview

5.2. Methodology

5.3. Assumptions and Key Parameters

5.4. Competitiveness Analysis

6. LATE STAGE RNAi THERAPEUTICS

6.1. Chapter Overview

6.2. Onpattro®

6.2.1. Drug Overview

6.2.2. Technology Overview

6.2.3. Current Development Status

6.2.4. Recent Clinical Trial Results

6.3. ARO-AAT

6.3.1. Drug Overview

6.3.2. Technology Overview

6.3.3. Current Development Status

6.3.4. Recent Clinical Trial Results

6.4. Fitusiran

6.4.1. Drug Overview

6.4.2. Technology Overview

6.4.3. Current Development Status

6.4.4. Recent Clinical Trial Results

6.5. Givosiran

6.5.1. Drug Overview

6.5.2. Technology Overview

6.5.3. Current Development Status

6.5.4. Recent Clinical Trial Results

6.6. Inclisiran

6.6.1. Drug Overview

6.6.2. Technology Overview

6.6.3. Current Development Status

6.6.4. Recent Clinical Trial Results

6.7. Lumasiran

6.7.1. Drug Overview

6.7.2. Technology Overview

6.7.3. Current Development Status

6.7.4. Recent Clinical Trial Results

6.8. QPI-1002

6.8.1. Drug Overview

6.8.2. Technology Overview

6.8.3. Current Development Status

6.8.4. Recent Clinical Trial Results

6.9. SYL 1001

6.9.1. Drug Overview

6.9.2. Technology Overview

6.9.3. Current Development Status

6.9.4. Recent Clinical Trial Results

6.10. Vigil-EWS

6.10.1. Drug Overview

6.10.2. Technology Overview

6.10.3. Current Development Status

6.10.4. Recent Clinical Trial Results

6.11. Vutrisiran

6.11.1. Drug Overview

6.11.2. Technology Overview

6.11.3. Current Development Status

6.11.4. Recent Clinical Trial Results

For more information, please click on the following link:

https://www.rootsanalysis.com/reports/view_document/rnai-therapeutics-market-2nd-edition-2019-2030/278.html

About Roots Analysis

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

Gaurav.Chaudhary@rootsanalysis.com

New Report Shares Details about the Global Preventive vaccine Market by 2030

2020-09-08T06:55:23.891Z

Technical advances, especially in the field of biotechnology, have led to the development of several next generation preventive vaccines, including recombinant vaccines, viral vector based vaccines and DNA vaccines, which have been demonstrated to elicit powerful immune responses, resulting in the development of immunological memory.

The USD 94 billion (by 2030) financial opportunity within the global preventive vaccine market has been analyzed across the following segments:

Route of Administration

· Intramuscular

· Subcutaneous

· Oral

· Intravenous

· Others

Type of Vaccine

· Pneumococcal Conjugate Vaccine

· Human Papilloma Virus Vaccine

· Rotavirus Vaccine

· Influenza Vaccine

· MMR Vaccine

· Tetanus and Diphtheria Booster Vaccine

· Varicella Vaccine

· DTaP-Hib-IPV Vaccine

· DTaP-HepB-Hib-IPV Vaccine

· Others

Type of Vaccine API

· Live, Attenuated Vaccine

· Inactivated Vaccine

· Conjugate Vaccine

· Subunit Vaccine

· Toxoid Vaccine

· Others

Target Patient Population

· Pediatric Patients

· Adult

Key Players

· GlaxoSmithKline

· Merck

· Sanofi Pasteur

· Pfizer

· Emergent BioSolutions

· CSL

· Others

Key Geographical Regions

· North America

· Europe

· Asia Pacific

· Rest of the World

The Global Preventive Vaccines Market, 2020-2030 report features the following companies, which we identified to be key players in this domain:

· Bio Farma

· Emergent BioSolutions

· GC Pharma

· GlaxoSmithKline

· Janssen

· Merck

· Novavax

· Pfizer

· Sanofi Pasteur

· Valneva

Table of Contents

1. Preface

2. Executive Summary

3. Introduction

4. Market Landscape

5. Company Competitiveness Analysis

6. Company Profiles

7. Clinical Trial Analysis

8. Ongoing Vaccine Development Initiatives for Complex Conditions

9. Funding and Investment Analysis

10. Market Sizing and Opportunity Analysis

11. Case-in-Point: Contract Manufacturing of Vaccines

12. Concluding Remarks

13. Executive Insights

14. Appendix 1: Tabulated Data

15. Appendix 2: List of Companies and Organizations

For more information, please click on the following link:

https://www.rootsanalysis.com/reports/view_document/preventive-vaccines/318.html

About Roots Analysis

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

Gaurav.Chaudhary@rootsanalysis.com

Prefilled syringes Market Trends 2020 and Industry Forecast 2030

2020-09-07T06:23:07.962Z

The financial opportunity within the prefilled syringes market has been analyzed across the following segments:

Target therapeutic area

· Autoimmune disorders

· Infectious diseases

· Neurological disorders

· Blood disorders

· Oncological disorders

· Psychiatric disorders

· Respiratory disorders

· Cardiovascular disorders

· Metabolic disorders

· Ophthalmic diseases

· Orthopedic disorders

· Others

Type of syringe

· Specialty syringes

Type of syringe barrel material

· Glass

· Plastic

Number of barrel chambers

· Single chamber

· Dual chamber

Key geographical regions

· North America

· Europe

· Latin America

· Asia Pacific

· Middle East and Africa

The Prefilled Syringes Market (5th Edition), 2020-2030 report features the following companies, which we identified to be key players in this domain:

· Becton Dickinson

· West Pharmaceutical

· Gerresheimer

· Ompi

· Schott

· Nipro

· WEGO Prefills Pharmaceutical Packaging

· Taisei Kako

· Terumo

· Aguettant

· Arte

· JO Pharma

· Pfizer Injectables

· Shandong Pharmaceutical Glass

· Shandong Zibo Minkang Pharmaceutical Packing

· Vetter Pharma

Satta King

Table of Contents

1. PREFACE

2. EXECUTIVE SUMMARY

3. INTRODUCTION TO PREFILLED SYRINGES

4 PREFILLED SYRINGES: MARKET OVERVIEW

5 PRODUCT COMPETITIVENESS ANALYSIS

6 MANUFACTURERS OF PREFILLED SYRINGES

7 NEEDLESTICK INJURIES

8 REGULATORY LANDSCAPE FOR PREFILLED SYRINGES

9 PREFILLED SYRINGE COMBINATION PRODUCTS: MARKET OVERVIEW

10 KEY THERAPEUTIC AREAS

11 PREFILLED SYRINGES: LIKELY DRUG CANDIDATES AND PARTNER ANALYSIS

12 BIG PHARMA INITIATIVES: PREFILLED SYRINGE COMBINATION PRODUCTS AND LIKELY CANDIDATES

13 SPECIALTY PREFILLED SYRINGES

14 RECENT DEVELOPMENTS AND APPLICATIONS OF PREFILLED SYRINGES

15 MARKET SIZING AND OPPORTUNITY ANALYSIS

16 GROWTH DRIVERS

17 SWOT ANALYSIS

18 PREFILLED SYRINGE COMPONENT MANUFACTURERS

19 FILL / FINISH SERVICE PROVIDERS FOR PREFILLED SYRINGES

20 CASE STUDY: AUTOINJECTORS

21 CONCLUDING REMARKS

22 INTERVIEW TRANSCRIPTS

23 APPENDIX 1: TABULATED DATA

24 APPENDIX 2: LIST OF COMPANIES

For more information, please click on the following link:

https://www.rootsanalysis.com/reports/view_document/prefilled-syringes-market/284.html

About Roots Analysis

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

Gaurav.Chaudhary@rootsanalysis.com